Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth

Paediatrics and Child Health

Volumn 16, Issue 9, 2011, Pages 590-598

  Pringsheim, Tamara ^a   Doja, Asif ^b,f   Belanger, Stacey ^c   Patten, Scott ^a   Casselman, Lisa ^d   Davidson, Jana ^e   Grisaru, Silviu ^a   Ho, Josephine ^a   Jabbal, Rekha ^g   MacKean, Gail ^d   McCrindle, Brian ^h   McLennan, John ^a   Palda, Valerie ^h   Panagiotopoulos, Constadina ^e   Pearce, Michelle ^h   Ponesse, Jonathan ^f   Thomas, Roger ^a   Waheed, Waqar ^a   Wilkes, Chris ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b Department of Pediatrics ^*  (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d Mental Health Commission of Canada 2008e2011   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

^g ALBERTA CHILDREN'S HOSPITAL   (Canada)

^h UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antipsychotic medications; Children; Extrapyramidal side effects

Indexed keywords

AMANTADINE; ARIPIPRAZOLE; BACLOFEN; BENZATROPINE; BIPERIDEN; BOTULINUM TOXIN; BRANCHED CHAIN AMINO ACID; CLONAZEPAM; DIAZEPAM; DIPHENHYDRAMINE; ETIRACETAM; LITHIUM; LORAZEPAM; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; PROCYCLIDINE; PROPRANOLOL; RESERPINE; RISPERIDONE; SECOND GENERATION ANTIPSYCHOTIC AGENT; SEROTONIN UPTAKE INHIBITOR; TETRABENAZINE; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG; VALPROIC ACID;

AKATHISIA; BEDTIME DOSAGE; CHILD HEALTH; CRANIAL NERVE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DOSE INCREASE; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; GAIT; HUMAN; MENTAL HEALTH; META ANALYSIS; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; PARKINSONISM; PRACTICE GUIDELINE; RATING SCALE; RECOMMENDED DRUG DOSE; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TREATMENT PLANNING; TREMOR;

EID: 80655144923     PISSN: 12057088     EISSN: None     Source Type: Journal    
DOI: 10.1093/pch/16.9.590     Document Type: Review

References (72)

1. Lane R, Glazer W, Hansen T, Berman W, Kramer S. Assessment of tardive dyskinesia using the abnormal involuntary movement scale. J Nerv Ment Dis 1985;173:353-7. (Pubitemid 15079180)
2. Knol W, Keijsers C, Jansen P, et al. Validity and reliability of the Simpson Angus Scale (SAS) in drug induced Parkinsonism in the elderly. Int J Geriatr Psychiatry 2009;24:183-9.
3. Janno S, Holi M, Tuisku K, Wahlbeck K. Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population. BMC Neurol 2005;5(5):doi:10.1186/147-2377-5-5.
4. Barnes T. A rating scale for drug induced akathisia. Br J Psychiatry 1989;154:672-6. (Pubitemid 19154942)
5. Chouinard G, Margolese H. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 2005;76:247-65. (Pubitemid 40804771)
6. Gharabawi GM, Bossie CA, Lasser RA, Turkoz I, Rodriguez S, Chouinard G. Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): Cross-scale comparison in assessing tardive dyskinesia. Schizophr Res 2005;77:119-28. (Pubitemid 41112206)
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Text revision (DSM-IV-TR). Washington (DC): American Psychiatric Association, 2000.
8. Tonda M, Guthrie S. Treatment of acute neuroleptic induced movement disorders. Pharmacotherapy 1994;14:543-60. (Pubitemid 24299954)
9. Neuhut R, Lindenmayer J, Silva R. Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication. A review. J Child Adolesc Psychopharmacol 2009;19:415-22.
10. Strawn J, Keck P, Caroff S. Neuroleptic malignant syndrome. Am J Psychiatry 2007;164:870-6. (Pubitemid 46972900)
11. Satterwaite T, Wolf D, Rosenheck R, Gur R, Caroff S. A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. J Clin Psychiatry 2008;69:1869-79
12. Gagrat D, Hamilton J, Belmaker R. Intravenous diazepam in the treatment of neuroleptic induced acute dystonia and akathisia. Am J Psychiatry 1978;135:1232-3. (Pubitemid 9006771)
13. Waugh W, Metts J. Severe extrapyramidal motor activity induced by prochlorperazine. Its relief by the intravenous injection of diphenhydramine. N Engl J Med 1960;162:353-4.
14. Arana G, Goff D, Baldessarini R, Keepers G. Efficacy of anticholinergic prophylaxis for neuroleptic induced acute dystonia. Am J Psychiatry 1988;145:993-6.
15. Hong I, Bishop J. Anticholinergic use in children and adolescents after initiation of antipsychotic therapy. Ann Pharmacother 2010;44:1171-80.
16. Gebhardt S, Härtling F, Hanke M, et al. Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment. Eur Child Adolesc Psychiatry 2006;15:371-82. (Pubitemid 44571709)
17. Haas M, Eerdekens M, Kushner S, et al. Efficacy, safety and tolerability of two risperidone dosing regimens in adolescent schizophrenia: Double-blind study. Br J Psychiatry 2009;194:158-64.
18. Pierre J. Extrapyramidal symptoms with atypical antipsychotics. Incidence, prevention and management. Drug Safety 2005;28:191-208. (Pubitemid 40364887)
19. Spivak B, Mester R, Abesgaus J, Wittenberg N, Adlersberg S. Clozapine treatment for neuroleptic induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry 1997;58:318-22. (Pubitemid 27362488)
20. Zadikoff C, Munhoz R, Asante A, et al. Movement disorders in patients taking anticonvulsants. J Neurol Neurosurg Psychiatry 2007;78:147-51. (Pubitemid 46220211)
21. Gelenberg A, Jefferson L. Lithium tremor. J Clin Psychiatry 1995;56:283-7.
22. Jamora D, Lim S, Pan A, Tan L, Tan E. Valproate induced parkinsonism in epilepsy patients. Mov Disord 2007;22:130-3. (Pubitemid 46382687)
23. Alvarez-Gomez M, Vaamonde J, Narbona J, Barao M, Baron P. Parkinsonian syndrome in childhood after sodium valproate administration. Clin Neuropharmacol 1993;16:451-5. (Pubitemid 23292101)
24. Koliscak L, Makela E. Selective serotonin reuptake inhibitor induced akathisia. J Am Pharm Assoc 2009;49:e28-36.
25. Silver H, Geraisy N, Schwartz M. No difference in the effect of biperiden and amantadine on parkinsonian and tardive dyskinesia type involuntary movements: A double blind crossover, placebo controlled study in medicated chronic schizophrenic patients. J Clin Psychiatry 1995;56:167-70.
26. Fann W, Lake C. Amantadine versus trihexyphenidyl in the treatment of neuroleptic induced parkinsonism. Am J Psychiatry 1976;133:940-3.
27. Kelly J, Zimmerman R, Abuzzahab F, Schiele B. A double blind study of amantadine hydrochloride versus benztropine mesylate in drug-induced parkinsonism. Pharmacology 1974;12:65-73.
28. Adler L, Peselow E, Rosenthal M, Angrist B. A controlled comparison of the effects of propranolol, benztropine, and placebo on akathisia. Psychopharmacol Bull 1993;29:283-6. (Pubitemid 23311537)
29. Resende Lima A, Soares-Weiser K, Bacaltchuk J, Barnes T. Benzodiazepines for neuroleptic induced acute akathisia. Cochrane Database Syst Rev 1999;(4):CD001950.
30. Poyurovsky M, Pashinian A, Weizman R, Fuchs C, Weizman A. Low dose mirtazapine: A new option in the treatment of antipsychotic induced akathisia. A randomized, double blind, placebo and propranolol controlled trial. Biol Psychiatry 2006;59:1071-7.
31. Kutcher S, Willliamson P, Mackenzie S, Marton P, Ehrlich M. Successful clonazepam treatment of neuroleptic induced akathisia in older adolescents and young adults: A double blind, placebo controlled study. J Clin Psychopharmacol 1989;9:403-6. (Pubitemid 20023020)
32. Tenback D, van Harten P, Slooff C, van Os J. Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia. J Psychopharmacol 2010;24:1031-5.
33. Dixon L, Thaker G, Conley R, Ross D, Cascella N, Tamminga C. Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double blind design. Schizophrenia Res 1993;10:267-71. (Pubitemid 23353442)
34. Greil W, Haag H, Rossnagl G, Ruther E. Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. Br J Psychiatry1984;145:304-10. (Pubitemid 14066482)
35. Louza MR, Bassitt DP. Maintenance treatment of severe tardive dyskinesia with clozapine: Five years follow-up. J Clin Psychopharmacol 2005;25:180-2. (Pubitemid 40395098)
36. Bassitt D, Neto M. Clozapine efficacy in tardive dyskinesia in schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 1998;248:209-11. (Pubitemid 28468502)
37. Levkovitch Y, Kronenberg J, Kayser N, Zvyagelski M, Gaoni B, Gadoth N. Clozapine for tardive dyskinesia in adolescents. Brain Dev 1995;17:213-5.
38. Ondo W, Hanna P, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: Assessment by randomized videotape protocol. Am J Psychiatry 1999;156:1279-81. (Pubitemid 29374894)
39. Jankovic J, Beach J. Long term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48:358-62. (Pubitemid 27087603)
40. Bhoopati P, Soares-Weiser K. Benzodiazepines for neuroleptic induced tardive dyskinesia. Cochrane Database Syst Rev 2006;(33):CD000205.
41. McGrath J, Soares-Weiser K. Vitamin E for neuroleptic induced tardive dyskinesia. Cochrane Database Syst Rev 2001;(4):CD000209.
42. Meco G, Fabrizio E, Epifanio A, et al. Levetiracetam in tardive dyskinesia. Clin Neuropharmacol 2006;29:265-8. (Pubitemid 44439999)
43. Konitsiotis S, Pappa S, Mantas C, Mavreas V. Levetiracetam in tardive dyskinesia: An open label study. Mov Disord 2006;21:1219-21. (Pubitemid 44336612)
44. Woods S, Saksa J, Baker B, Cohen S, Tek C. Effects of levetiracetam on tardive dyskinesia: A randomized, double blind, placebo controlled study. J Clin Psychiatry 2008;69:546-54. (Pubitemid 351792328)
45. Richardson M, Small A, Read L, Chao H, Clelland J. Branched chain amino acid treatment of tardive dyskinesia in children and adolescents. J Clin Psychiatry 2004;65:92-6.
46. Kumra S, Jacobsen L, Lenane M, et al. Case series: Spectrum of neuroleptic-induced movement disorders and extrapyramidal side effects in childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 1998;37:221-6.
47. Campbell M, Armenteros J, Malone R, Adams P, Eisenberg Z, Overall J. Neuroleptic related dyskinesias in autistic children: A prospective longitudinal study. J Am Acad Child Adolesc Psychiatry 1997;36:835-43. (Pubitemid 27250449)
48. Burke R, Fahn S, Jankovic J, et al. Tardive dystonia: Late onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982;32:1335-46. (Pubitemid 13203738)
49. Aggarwal A, Jiloha R. Olanzapine induced tardive dystonia. Indian J Pharmacol 2008;40:237-8.
50. Rauchverger B, Isakov V, Jabarin M. Olanzapine induced tardive dystonia successfully treated by tetrabenazine. J Neuropsychiatry Clin Neurosci 2007;19:484-5. (Pubitemid 350156124)
51. Fdhil H, Krebs M, Bayle F, Vanelle J, Olie J. Risperidone induced tardive dystonia: A case of torticollis. Encephale 1998;24:581-3.
52. Pringsheim T. Missed case of tardive dystonia in an adolescent girl treated with risperidone. J Child Adolesc Psychopharmacol 2011. (In press)
53. Oommen E, Chand P, Sharma P. Aripiprazole induced tardive dystonia. Prim Care Companion J Clin Psychiatry 2006;8:378-9.
54. Tibrewal P, Zutshi A, Math S. Tardive dystonia and ziprasidone: A case report. Prim Care Companion J Clin Psychiatry 2008;10:71-2. (Pubitemid 351879946)
55. Papapetropoulos S, Wheeler S, Singer C. Tardive dystonia associated with ziprasidone. Am J Psychiatry 2005;162:2191.
56. Adityanjee, Esterera AB. Successful treatment of tardive dystonia with clozapine. Biol Psychiatry 1996;39:1064-5.
57. Friedman J. Clozapine treatment of psychosis in patients with tardive dystonia: Report of three cases. Mov Disord 1994;9:321-4. (Pubitemid 24150118)
58. Conus P, Zullino D, Baumann P. Clozapine is more efficacious for tongue dystonia than olanzapine. Psychopharmacology 2002;162:89. (Pubitemid 34639564)
59. Monteiro L. Tardive dyskinesia controlled by anticholinergic agents. Clin Neuropharmacol 1985;8:372-6. (Pubitemid 16183923)
60. Chatterjee A, Forrest GM, Giladi N, Trosch R. Botulinum toxin in the treatment of tardive dystonia. J Clin Psychopharmacol 1997;17:497-8. (Pubitemid 28389197)
61. Rosse R, Allen A, Lux W. Baclofen treatment in a patient with tardive dystonia. J Clin Psychiatry 1986;47:474-5. (Pubitemid 16027685)
62. Dressler D, Oeljeschlager R, Ruther E. Severe tardive dystonia: Treatment with continuous intrathecal baclofen administration. Mov Disord 1997;12:585-7. (Pubitemid 27322889)
63. Franzini A, Marras C, Ferroli P, et al. Long term high frequency bilateral pallidal stimulation for neuroleptic induced tardive dystonia. Report of two cases. J Neurosurg 2005;102:721-5. (Pubitemid 43186678)
64. Burke R, Kang U, Jankovic J, Miller L, Fahn S. Tardive akathisia: An analysis of clinical features and response to open therapeutic trials. Mov Disord 1989;4:157-75. (Pubitemid 19128939)
65. Yassa R, Iskandar H, Nastase C. Propranolol in the treatment of tardive akathisia: A report of two cases. J Clin Psychopharmacol 1988;8:283-5.
66. Yassa R, Bloom D. Lorazepam and anticholinergics in tardive akathisia. Biol Psychiatry 1990;27:463-4. (Pubitemid 20083780)
67. Levin H, Chengappa K, Kambhampati R, Mahdavi N, Ganguli R. Should chronic treatment-refractory akathisia be an indication for the use of clozapine in schizophrenic patients? J Clin Psychiatry 1992;53:248-51.
68. Lexicomp Online. 〈http://online.lexi.com/crlsql/servlet/ crlonline〉 (Accessed on October 3, 2011).
69. Thomson Reuters Micromedex. 〈www.micromedex.com〉 (Accessed on October 3, 2011).
70. Singer HS, Mink JW, Gilbert DL, Jankovic J. Movement Disorders in Childhood. Saunders, Elsevier 2010:249-60.
71. Marrosu F, Marrosu G, Rachel M, Biggio G. Paradoxical reactions elicited by diazepam in children with classic autism. Funct Neurol 1987;2:355-61. (Pubitemid 18039190)
72. Mancuso C, Tanzi M, Gabay M. Paradoxical reactions to benzodiazepines: Literature review and treatment options. Pharmacotherapy 2004;24:1177-85. (Pubitemid 39128841)